Mark De Souza

Mark de Souza, PhD is former CEO / Exec Chair of Lotus Tissue Repair (Shire, $325MM), PellePharm, NFlection Therapeutics, Wings Therapeutics, FIBRX Derm, and others. He is the former VP of Business Development at Dyax (Shire $6B M&A), KALBITOR and TAKHZYRO for hereditary angioedema.